Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$2.75
-0.4%
$3.22
$1.72
$3.84
$25.85M1.5524,663 shs4,308 shs
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$56.00
$55.66
$17.15
$56.48
$1.14B2.34301,073 shsN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
C$1.59
-5.9%
C$1.47
C$1.20
C$4.49
C$119.92M1.4973,850 shs70,084 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-1.41%-7.92%-17.94%+11.60%-3.15%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00%0.00%0.00%0.00%+108.49%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
+4.32%+6.29%+9.03%+21.58%-22.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.2456 of 5 stars
3.55.00.00.02.60.81.3
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
0.9315 of 5 stars
3.50.00.00.02.20.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.00118.18% Upside
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
2.00
HoldN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
3.00
BuyC$6.00277.36% Upside

Current Analyst Ratings

Latest OBD, CIR, ACST, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$3.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$786.92M1.45$4.77 per share11.74$7.81 per share7.17
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AC$0.38 per share4.22C$0.37 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$19.39M$1.3740.8819.51N/A3.40%35.32%5.21%N/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$27.75M-C$0.41N/AN/AN/A-102.66%-55.47%8/12/2024 (Estimated)

Latest OBD, CIR, ACST, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
-C$0.15-C$0.05+C$0.10-C$0.05N/AN/A
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3.34
2.29
1.46
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
1.54
9.01
8.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
96.16%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.98%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
1.00%
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
6.24%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3,06020.39 million20.19 millionOptionable
Oncolytics Biotech Inc. stock logo
ONC
Oncolytics Biotech
2975.42 millionN/ANot Optionable

OBD, CIR, ACST, and ONC Headlines

SourceHeadline
Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational HighlightsOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights
finanznachrichten.de - May 10 at 7:15 AM
Oncolytics Biotech (TSE:ONC) Share Price Crosses Above 200-Day Moving Average of $1.68Oncolytics Biotech (TSE:ONC) Share Price Crosses Above 200-Day Moving Average of $1.68
americanbankingnews.com - May 10 at 4:18 AM
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024
msn.com - May 9 at 9:14 PM
FN Media Group: Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036FN Media Group: Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
finanznachrichten.de - May 9 at 4:14 PM
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
prnewswire.co.uk - May 9 at 4:14 PM
Stocks in play: Oncolytics Biotech Inc.Stocks in play: Oncolytics Biotech Inc.
ca.finance.yahoo.com - May 9 at 4:14 PM
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational HighlightsOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
finance.yahoo.com - May 9 at 4:14 PM
USA News Group: Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbUSA News Group: Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
finanznachrichten.de - May 9 at 11:13 AM
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to ClimbBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
prnewswire.co.uk - May 9 at 11:13 AM
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceOncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 8 at 7:10 AM
Oncolytics Biotech (ONC) Scheduled to Post Earnings on ThursdayOncolytics Biotech (ONC) Scheduled to Post Earnings on Thursday
americanbankingnews.com - May 2 at 4:42 AM
Krystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 virusKrystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 virus
pharmaceutical-technology.com - April 23 at 9:08 AM
Outrun Therapeutics announces launch with $10m seed fundingOutrun Therapeutics announces launch with $10m seed funding
pharmaceutical-technology.com - April 18 at 7:38 AM
Biotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiesBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universities
carolinapublicpress.org - April 17 at 10:38 AM
Stocks in play: Oncolytics Biotech® Inc.Stocks in play: Oncolytics Biotech® Inc.
ca.finance.yahoo.com - April 11 at 3:56 PM
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
finance.yahoo.com - April 11 at 8:38 AM
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
markets.businessinsider.com - April 10 at 6:01 PM
Oncolytics Biotech is undervalued, Raymond James saysOncolytics Biotech is undervalued, Raymond James says
cantechletter.com - April 5 at 3:37 PM
Closing Bell: Oncolytics Bio down on Friday (ONC)Closing Bell: Oncolytics Bio down on Friday (ONC)
theglobeandmail.com - March 16 at 10:14 AM
Futures Retreat SharplyFutures Retreat Sharply
msn.com - March 11 at 4:05 PM
Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
finanznachrichten.de - March 6 at 4:39 PM
Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
finanznachrichten.de - March 6 at 4:39 PM
A Preview Of Oncolytics Biotechs EarningsA Preview Of Oncolytics Biotech's Earnings
benzinga.com - March 6 at 4:39 PM
Oncolytics Biotech Inc ONCOncolytics Biotech Inc ONC
morningstar.com - March 2 at 6:22 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
CIRCOR International logo

CIRCOR International

NYSE:CIR
CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.
Oncolytics Biotech logo

Oncolytics Biotech

TSE:ONC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.